All DPP-4 Inhibitors to Undergo Major Price Reductions Due to Market Expansion of Januvia/Glactiv; Re-pricing Could Affect SGLT-2 Inhibitors as Well

The knife is about to be taken to NHI prices of dipeptidyl peptidase-4 (DPP-4) inhibitors, the number and sales of which have grown rapidly since their debut just a few years ago at the end of 2009. All seven active...read more